Log in to save to my catalogue

156 Discovery of TSC-100: A natural HA-1-specific TCR to treat leukemia following hematopoietic stem...

156 Discovery of TSC-100: A natural HA-1-specific TCR to treat leukemia following hematopoietic stem...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d8b81dd10b4b49dd8f55a003956d8da4

156 Discovery of TSC-100: A natural HA-1-specific TCR to treat leukemia following hematopoietic stem cell transplant therapy

About this item

Full title

156 Discovery of TSC-100: A natural HA-1-specific TCR to treat leukemia following hematopoietic stem cell transplant therapy

Publisher

London: BMJ Publishing Group LTD

Journal title

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A170-A170

Language

English

Formats

Publication information

Publisher

London: BMJ Publishing Group LTD

More information

Scope and Contents

Contents

BackgroundApproximately 30–40% of AML patients relapse following allogeneic hematopoietic stem cell transplant therapy, leaving them with very few treatment options.1 2 Rare patients that naturally develop an HA-1-specific graft-versus-leukemia T cell response, however, show substantially lower relapse rates.3 4 HA-1 (VLHDDLLEA, genotype RS_1801284...

Alternative Titles

Full title

156 Discovery of TSC-100: A natural HA-1-specific TCR to treat leukemia following hematopoietic stem cell transplant therapy

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_d8b81dd10b4b49dd8f55a003956d8da4

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d8b81dd10b4b49dd8f55a003956d8da4

Other Identifiers

E-ISSN

2051-1426

DOI

10.1136/jitc-2020-SITC2020.0156

How to access this item